| (Values in U.S. Thousands) | Mar, 2020 | Dec, 2019 | Sep, 2019 | Jun, 2019 | Mar, 2019 |
| Sales | 0 | 530 | 3,380 | 10,790 | 7,020 |
| Sales Growth | -100.00% | -84.32% | -68.67% | +53.70% | -5.26% |
| Net Income | -3,480 | -2,730 | -3,250 | -660 | -4,750 |
| Net Income Growth | -27.47% | +16.00% | -392.42% | +86.11% | -21.48% |
Conatus Pharmaceutic (CNAT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California.